ClinicalTrials.gg
Active, not recruitingNCT04573881#HOPE4LIVERUpdated Jan 12, 2026Results posted

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)

An interventional study of HistoSonics System in Liver Neoplasms, Hepatocellular Carcinoma and Liver Metastases, sponsored by HistoSonics, Inc.. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Primary conditionCarcinoma, HepatocellularRegistry: Liver NeoplasmsReclassifiedWhy we changed it
Registry
Liver Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Hepatocellular
Why
  1. The study's listed conditions name Carcinoma, Hepatocellular, a narrower term within Liver Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by HistoSonics, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Carcinoma, Hepatocellular with a site in Germany — 23 open to participants now, 38 under way, 9 of them phase 3. Carcinoma, Hepatocellular · Germany.

Enrollment
109th of 124
24 · median 128
Started
2021
with 9 others
No phase
15 of 149
5 open now
Primary completion
2022-09
later than 2 of 37 live
Registered
110th of 149
by date

Among the 149 studies in Carcinoma, Hepatocellular with a site in Germany, this one is the 109th largest by enrollment of the 124 interventional ones that give a count, is one of 10 that started in 2021, is one of 15 with no phase, reaches primary completion later than 2 of the 37 other live ones, and was the 110th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

23 of the 149 studies in Carcinoma, Hepatocellular with a site in Germany are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Carcinoma, Hepatocellular with a site in Germany, or all of them as a file.
02

Study summary

This trial is a single arm, non-randomized prospective trial. The objective of this trial is to evaluate the efficacy and safety of the HistoSonics System for the treatment of primary or metastatic tumors located in the liver.

Read the detailed description

This trial is a single arm, non-randomized, multicenter, prospective trial. Following histotripsy treatment of liver tumor(s), subjects will undergo imaging ≤36 hours post-index procedure to determine technical success. Subjects will then be followed for 30 days. Additionally, subjects will be evaluated at 6 months and followed annually for up to five (5) years post-index procedure.

03

Conditions studied

  • Liver Neoplasms
  • Hepatocellular Carcinoma
  • Liver Metastases

Browse trials for

04

In context

Carcinoma, Hepatocellular Reclassified

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

This study's enrollment of 24 is below the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

HistoSonics, Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Compared within Carcinoma, Hepatocellular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Liver Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥18 years of age
  2. Subject has signed the Ethics Committee (EC) or Institutional Review Board (IRB) approved trial Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments
  3. Subject is diagnosed with hepatocellular carcinoma (HCC) or liver (mets) from other primary cancers

    • Subject that is an HCC patient must have a targetable lesion(s) which meets the United Network for Organ Sharing and Organ Procurement and Transplantation Network (UNOS-OPTN) class 5 diagnostic criteria for HCC
    • Subject that is diagnosed with liver metastases must have prior diagnosis of primary tumor or metastatic tumor to identify the primary cancer type. Subjects must have untreated new or growing liver tumor(s) radiologically consistent with metastases. Note: A is required to confirm metastatic disease and the pathological results must be obtained prior to the index procedure (does not need to be a targeted tumor(s))
  4. Subject is able to undergo general anesthesia
  5. Subject has a Score of A or B (up to B8)
  6. Subject has an Performance Status (ECOG PS) grade 0-2 at baseline screening
  7. Subject meets the following functional criteria, ≤7 days prior to the planned index-procedure date:

    • Liver function: (ALT) \<2.5x (ULN) and Aspartate transaminase (AST) \<2.5x ULN and \<2.5 ULN, and
    • Renal function: serum creatinine \<2x ULN, and
    • Hematologic function: >1.0 x 10\^9/L and >50 x 10\^9/L
  8. Subject has an (INR) score of \<2.0 , ≤7 days prior to the planned index procedure date
  9. Subject has not responded to and/or has and/or is intolerant of other available therapies including locoregional therapies, chemotherapy, immunotherapy and targeted therapies.
  10. The tumor(s) selected for histotripsy treatment must be ≤3 cm in longest diameter
  11. Subject has an adequate acoustic window to visualize targeted tumor(s) using ultrasound imaging
  12. Subject has a maximum of three (3) tumors to be treated with histotripsy during the index procedure, regardless of how many tumors the subject has.

Note: If the subject is treated with surgical resection prior to the index procedure, the resection must be performed ≥2 weeks prior to the planned index-procedure date

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the trial period
  2. Subject is enrolled in another trial and/or is taking investigational medication and/or has been treated with an investigational device ≤30-days prior to planned index procedure date
  3. In the Investigator's opinion, the subject has co-morbid disease(s) or condition(s) that would cause undue risk and preclude safe use of the HistoSonics System
  4. Subject has a serum creatinine >2.0 mg/dL or estimated (EGFR) \<30, unless on dialysis
  5. Subject has major surgical procedure or significant traumatic injury ≤2 weeks prior to the planned index procedure or not fully recovered ( grade 1 or better) from side effects/complications of such procedure or trauma
  6. Subject has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from any adverse effects (except alopecia, fatigue, nausea, vomiting and peripheral neuropathy) related to previous anti-cancer therapy
  7. Subject has a history of, or suspected to have, bleeding disorders that are uncorrectable
  8. Subject has a coagulopathy that is uncorrectable
  9. Subject has a planned cancer treatment (e.g. resection, chemotherapy, etc.) after the planned index-procedure date and prior to completion of the 30-day follow-up visit
  10. Subject has previous treatment with bevacizumab that has not been discontinued >40 days prior to the planned index-procedure date
  11. Subject has planned bevacizumab treatment prior to completion of the 30-day follow-up visit
  12. Subject has previous treatments with chemotherapy and/or radiotherapy that has not been discontinued ≥2 weeks prior to the planned index-procedure date and has not recovered (CTCAE grade 1 or better) from related toxicity (except alopecia and peripheral neuropathy)
  13. Subject has previous treatment with immunotherapies that has not been discontinued ≥4 weeks prior to the planned index-procedure date and has not recovered from related toxicity (CTCAE grade 1 or better)
  14. Subject has a less than six (\<6) months
  15. In the opinion of the Investigator, histotripsy is not a treatment option for the subject
  16. Subject has a concurrent condition that, in the investigator's opinion, could jeopardize the safety of the subject or compliance with the protocol
  17. Subjects' tumor(s) is not treatable by the System's working ranges (refer to User Manual)
  18. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated
  19. Subjects' targeted tumor(s) has/have had prior locoregional therapy (e.g. ablation, embolization, radiation)
  20. Subject is eligible for surgical resection
  21. Targeted tumor(s) treatment volume overlaps a non-targeted tumor visible via imaging
  22. The targeted tumor(s) is not clearly visible with diagnostic ultrasound and computed tomography (CT) or magnetic resonance (MR) imaging
  23. The targeted tumor(s) is located in liver segment 1
  24. The Planned Treatment Volume intended to cover the targeted tumor includes or encompasses any portion of the main portal vein, common hepatic duct, common bile duct, gallbladder or stomach/bowel
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    HistoSonics System

    Device: HistoSonics System

Interventions

  • DeviceHistoSonics System

    The HistoSonics System - intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.

    Also known as: Histotripsy

07

What researchers measure

Primary outcomes

  1. Primary Efficacy: Technical Success

    Technical success, defined as the treatment volume/treatment dimensions being greater than or equal to the targeted tumor, and with complete tumor coverage, via computed tomography (CT) or magnetic resonance (MR) imaging. \[Core Laboratory Adjudicated\]

    Time frame: ≤36 hours post-index procedure

  2. Primary Safety: Procedure-Related Major Complications

    Number of index procedure related major complications, including device-related events defined as Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher toxicities observed up to 30-days post index-procedure. \[Clinical Events Committee Adjudicated\]

    Time frame: 30 days post-index procedure

Secondary outcomes

  1. Secondary Efficacy: Technique Efficacy

    Technique efficacy, defined as the lack of a nodular or mass-like area of enhancement within or along the edge of the treatment volume assessed via CT or MR imaging at 30-days post-procedure. \[Core Laboratory Adjudicated\]

    Time frame: 30 days post-index procedure

  2. Secondary Safety: All Adverse Events

    Number of adverse events (serious and non-serious) reported within 30 days post-index procedure. \[Clinical Events Committee Adjudicated\]

    Time frame: 30 days post-index procedure

08

Results

Posted Aug 19, 2024
Limitations and caveats
Due to completion of the primary analysis in #HOPE4LIVER US (NCT04572633) that included powered efficacy and safety hypothesis testing on combined US and EU/UK participants, #HOPE4LIVER EU/UK trial enrollment was stopped early. Therefore, there is an insufficient number of target participants needed to achieve target power and statistically reliable results for the primary endpoints for #HOPE4LIVER EU/UK.

Participant flow

The trial was designed to enroll up to 45 participants; however, enrollment was stopped after 24 participants were enrolled due to completion of the primary analysis of #HOPE4LIVER US (NCT04572633). The primary analysis assessed the primary and secondary endpoints at 30 days using pooled data from #HOPE4LIVER EU/UK and #HOPE4LIVER US after a total of 40 evaluable participants enrolled between the two trials. Follow-up beyond 30 days is ongoing.

Participant flow — Overall Study
MilestoneHistoSonics System
Started24
Completed0
Not completed24
Withdrew: Participant in active follow-up at 30 days24

Outcome measures

PrimaryPrimary Efficacy: Technical Success

Technical success, defined as the treatment volume/treatment dimensions being greater than or equal to the targeted tumor, and with complete tumor coverage, via computed tomography (CT) or magnetic resonance (MR) imaging. \[Core Laboratory Adjudicated\]

Time frame:
≤36 hours post-index procedure
Reported as:
Number · percentage of tumors
Primary Efficacy: Technical Success
percentage of tumorsHistoSonics System
Primary Efficacy: Technical Success100 (100 to 100)
PrimaryPrimary Safety: Procedure-Related Major Complications

Number of index procedure related major complications, including device-related events defined as Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher toxicities observed up to 30-days post index-procedure. \[Clinical Events Committee Adjudicated\]

Time frame:
30 days post-index procedure
Reported as:
Number · percentage of participants
Primary Safety: Procedure-Related Major Complications
percentage of participantsHistoSonics System
Primary Safety: Procedure-Related Major Complications12.5 (4.3 to 31.0)
SecondarySecondary Efficacy: Technique Efficacy

Technique efficacy, defined as the lack of a nodular or mass-like area of enhancement within or along the edge of the treatment volume assessed via CT or MR imaging at 30-days post-procedure. \[Core Laboratory Adjudicated\]

Time frame:
30 days post-index procedure
Reported as:
Number · percentage of tumors
Secondary Efficacy: Technique Efficacy
percentage of tumorsHistoSonics System
Secondary Efficacy: Technique Efficacy100 (100 to 100)
SecondarySecondary Safety: All Adverse Events

Number of adverse events (serious and non-serious) reported within 30 days post-index procedure. \[Clinical Events Committee Adjudicated\]

Time frame:
30 days post-index procedure
Reported as:
Number · adverse events
Secondary Safety: All Adverse Events
adverse eventsHistoSonics System
Secondary Safety: All Adverse Events38

Adverse events

Collected over Enrollment through 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HistoSonics System0/24 (0%)7/24 (29.2%)14/24 (58.3%)
Most frequent serious events
Most frequent serious events
EventHistoSonics System
Hepatic failureHepatobiliary disorders1/24
Postoperative thrombosisInjury, poisoning and procedural complications1/24
Procedural painInjury, poisoning and procedural complications1/24
Splenic haematomaBlood and lymphatic system disorders1/24
Melaena/MelenaGastrointestinal disorders1/24
Chest painGeneral disorders1/24
SepsisInfections and infestations1/24
Pleuritic painRespiratory, thoracic and mediastinal disorders1/24
Most frequent other events
Showing 10 of 17
Most frequent other events
EventHistoSonics System
Procedural painInjury, poisoning and procedural complications6/24
PyrexiaGeneral disorders4/24
Abdominal painGastrointestinal disorders3/24
Anaemia/AnemiaBlood and lymphatic system disorders2/24
Abdominal pain upperGastrointestinal disorders1/24
ConstipationGastrointestinal disorders1/24
AstheniaGeneral disorders1/24
DiscomfortGeneral disorders1/24
Localized oedemaGeneral disorders1/24
Procedural nauseaInjury, poisoning and procedural complications1/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)HistoSonics System
Mean62.9 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)HistoSonics System
Female14
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HistoSonics System
Hispanic or Latino4
Not Hispanic or Latino20
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)HistoSonics System
White23
Other1
Type of tumor
Type of tumor(Participants)HistoSonics System
Hepatocellular carcinoma7
Liver metastasis17
09

Study locations

6 sites
10

References and documents

Publications

  • Wah TM, Pech M, Thormann M, Serres X, Littler P, Stenberg B, Lenton J, Smith J, Wiggermann P, Planert M, Vidal-Jove J, Torzilli G, Solbiati L. A Multi-centre, Single Arm, Non-randomized, Prospective European Trial to Evaluate the Safety and Efficacy of the HistoSonics System in the Treatment of Primary and Metastatic Liver Cancers (#HOPE4LIVER). Cardiovasc Intervent Radiol. 2023 Feb;46(2):259-267. doi: 10.1007/s00270-022-03309-6. Epub 2022 Nov 15. PubMed 36380155 ↗
  • Mendiratta-Lala M, Wiggermann P, Pech M, Serres-Creixams X, White SB, Davis C, Ahmed O, Parikh ND, Planert M, Thormann M, Xu Z, Collins Z, Narayanan G, Torzilli G, Cho C, Littler P, Wah TM, Solbiati L, Ziemlewicz TJ. The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors. Radiology. 2024 Sep;312(3):e233051. doi: 10.1148/radiol.233051. PubMed 39225612 ↗
  • Ziemlewicz TJ, Critchfield JJ, Mendiratta-Lala M, Wiggermann P, Pech M, Serres-Creixams X, Lubner M, Wah TM, Littler P, Davis CR, Narayanan G, White SB, Ahmed O, Collins ZS, Parikh ND, Planert M, Thormann M, Torzilli G, Solbiati LA, Cho CS. The #HOPE4LIVER Single-arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors: One-year Update of Clinical Outcomes. Ann Surg. 2025 Dec 1;282(6):908-916. doi: 10.1097/SLA.0000000000006720. Epub 2025 Apr 9. PubMed 40201962 ↗
  • Wong BO, Fan CM, Shyn PB, Wang J. Vascular complications following histotripsy of hepatocellular carcinoma. Int J Hyperthermia. 2025 Dec;42(1):2603108. doi: 10.1080/02656736.2025.2603108. Epub 2025 Dec 16. PubMed 41403239 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Sep 2022, 15 months.

Results were first posted in Aug 2024, 1 year 10 months after primary completion.

Of 385 interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 75. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2020
First posted
Oct 5, 2020
StartActual
Jun 4, 2021
Primary completionActual
Sep 29, 2022
CompletionEst.
Aug 2027
Results first posted
Aug 19, 2024
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04573881
Lead sponsor
HistoSonics, Inc.
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Jun 4, 2021
Primary completion
Sep 29, 2022
Completion
Aug 2027 (estimated)
Results posted
Aug 19, 2024
Last update
Jan 12, 2026

Study contacts

Luigi A Solbiati, MD
principal investigator · Humanitas Research Hospital IRCCS, Rozzano-Milan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion